Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 EXCALIBER-RRMM results showing median progression-free survival of 42 months with ZENBEXUS-based treatment versus 20 months with the comparator regimen.
AstraZeneca (NASDAQ:AZN) has reportedly engaged in early-stage negotiations regarding a potential merger with Bristol Myers Squibb (NYSE:BMY).
Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenues of $13.0 billion, representing a 6% increase from the prior year.
Bristol Myers Squibb (NYSE:BMY) announced that the U.S. Food and Drug Administration accepted its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone, known as MeziKd, for patients with relapsed or refractory multiple myeloma.
Bristol Myers Squibb (NYSE:BMY) reported positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel) in adults with quadruple-class exposed relapsed and refractory multiple myeloma.
